Back to top
more

PerkinElmer, Inc. (PKI)

(Delayed Data from NYSE)

$96.59 USD

96.59
692,880

+1.71 (1.80%)

Updated May 3, 2019 04:03 PM ET

After-Market: $96.59 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

PerkinElmer (PKI) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

PerkinElmer's (PKI) second-quarter results benefit from strong segmental performance.

PerkinElmer (PKI) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

PerkinElmer (PKI) delivered earnings and revenue surprises of 17.43% and 9.84%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

PerkinElmer (PKI) to Post Q2 Earnings: What's in the Cards?

by Zacks Equity Research

PerkinElmer's (PKI) second-quarter results are likely to reflect strong performance at Diagnostics segment.

PerkinElmer (PKI) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

PerkinElmer (PKI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

If You Invested $1000 in PerkinElmer 10 Years Ago, This Is How Much You'd Have Now

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) continues to gain traction on a solid product portfolio and improving margins. However, forex woes linger.

Debanjana Dey headshot

Oncology Space Gains Momentum in 2021: 5 Stocks to Focus on

by Debanjana Dey

Oncology stocks like OncoCyte (OCX), PerkinElmer (PKI), Catalent (CTLT), Cardiff Oncology (CRDF) and NovoCure (NVCR) are expected to continue their run over the next few months.

Catalent (CTLT) to Enhance Its Portfolio via RheinCell Buyout

by Zacks Equity Research

Catalent (CTLT) expects to strengthen its position in new therapeutic areas and boost its cell therapy portfolio via the latest acquisition.

Here's How Investors Can Find Strong Computer and Technology Stocks with the Zacks ESP Screener

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Agilent (A) Expands Presence in LC Market With New Systems

by Zacks Equity Research

Agilent (A) expands its Bio Liquid Chromatography solutions portfolio with three new systems to fulfil the needs of biopharma industry.

PerkinElmer (PKI) to Boost Portfolio via SIRION Acquisition

by Zacks Equity Research

PerkinElmer (PKI) expects to be able to support its cell and gene therapy workflows, and expand its existing research solutions via the latest buyout.

If You Invested $1000 in PerkinElmer a Decade Ago, This is How Much It'd Be Worth Now

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

PerkinElmer (PKI) Up 1.9% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PerkinElmer (PKI) Gets COVID-19 Solutions Contract Extension

by Zacks Equity Research

PerkinElmer's (PKI) COVID-19 Lighthouse Laboratory contract extended through March 2022 to align with NHS Test and Trace's testing strategy.

Here's How Much a $1000 Investment in PerkinElmer Made 10 Years Ago Would Be Worth Today

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) continues to gain traction on a solid product portfolio and improving margins. However, forex woes linger.

Zacks Industry Outlook Highlights: Mettler-Toledo International, PerkinElmer and Bruker Corp

by Zacks Equity Research

Zacks Industry Outlook Highlights: Mettler-Toledo International, PerkinElmer and Bruker Corp

Aniruddha Ganguly headshot

3 Stocks to Watch on Rising Demand for Scientific Instruments

by Aniruddha Ganguly

The Zacks Instruments - Scientific industry participants like Mettler-Toledo (MTD), PerkinElmer (PKI) and Bruker Corporation (BRKR) are gaining from strong life science, pharmaceutical and academic end-market demand as well as rising healthcare spending.

LHC Group (LHCG) Forays Into Oregon With New Acquisition

by Zacks Equity Research

LHC Group (LHCG) acquires Home 'n Hospice to expand its existing footprint in Idaho.

PerkinElmer's (PKI) COVID-19 Test Kit Part of Investigative Study

by Zacks Equity Research

PerkinElmer's (PKI) test kit, which is currently being used in an investigative study, is aimed at accelerating the vaccine development and treatments against COVID-19.

PerkinElmer (PKI) to Boost Immunodiagnostics Unit With Buyout

by Zacks Equity Research

PerkinElmer (PKI) enters into an agreement to acquire IDS, which will enable the former to grow its overall Diagnostics business, particularly its immunodiagnostics unit.

If You Invested $1000 in PerkinElmer a Decade Ago, This is How Much It'd Be Worth Now

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

PerkinElmer (PKI) Boosts Cell Biology Portfolio With Buyout

by Zacks Equity Research

PerkinElmer (PKI) enters into an agreement to acquire Nexcelom that will enable the former to boost its efforts when it comes to solutions for drug discovery.

PerkinElmer (PKI) Moves 6.9% Higher: Will This Strength Last?

by Zacks Equity Research

PerkinElmer (PKI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

PerkinElmer (PKI) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

PerkinElmer's (PKI) first-quarter results benefit from strong segmental performance.